Back to top

VKTX: Buy Rating Backed by VK2735’s Potential to Transform Obesity Maintenance Therapy Ahead of Key Phase I Data

William Blair analyst Andy Hsieh has reiterated their bullish stance on VKTX stock, giving a Buy rating yesterday. Andy Hsieh has given his Buy rat...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viking Therapeutics, Inc. (VKTX)